BioCentury | Jan 5, 2015
Clinical News

THR-18: Additional Phase IIa data

...D-Pharm, which previously reported interim data from the trial, gained THR-18 through its merger with Thrombotech Ltd....
BioCentury | Mar 10, 2014
Clinical News

THR-18: Interim Phase IIa data

...to a second cohort evaluating 0.54 mg/kg THR-18. D-Pharm gained THR-18 through its merger with Thrombotech Ltd....
BioCentury | Oct 21, 2013
Clinical News

THR-18: Phase IIa start

...in about 30 patients with acute ischemic stroke. D-Pharm gained THR-18 through its merger with Thrombotech Ltd....
BioCentury | May 28, 2012
Company News

D-Pharm, Thrombotech deal

...D-Pharm will merge with stroke company Thrombotech in a stock deal. Shareholders of Thrombotech will own...
...own stroke therapy DP-b99 due to lack of efficacy. The combined company's pipeline will include: Thrombotech's...
...patients with complex partial epilepsy (see BioCentury, March 5). D-Pharm Ltd. (Tel Aviv:DPRM), Rehovot, Israel Thrombotech Ltd....
BioCentury | May 28, 2012
Finance

Highlights of weekly biotech stock moves

...after announcing it will merge with stroke company Thrombotech Ltd. in a stock deal. Shareholders of Thrombotech...
BioCentury | May 25, 2012
Company News

D-Pharm, Thrombotech to merge

...will merge with stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal. Shareholders of Thrombotech...
...own stroke therapy DP-b99 due to lack of efficacy. The combined company's pipeline will include: Thrombotech's...
BioCentury | Mar 5, 2012
Company News

D-Pharm, Thrombotech deal

...D-Pharm said it is in negotiations to acquire stroke company Thrombotech in a stock deal after...
...technology. The product has completed a Phase II trial in patients with complex partial epilepsy. Thrombotech's...
...in Phase II testing to treat acute ischemic stroke. D-Pharm Ltd. (Tel Aviv:DPRM), Rehovot, Israel Thrombotech Ltd....
BioCentury | Mar 5, 2012
Finance

Highlights of weekly biotech stock moves

...NIS1.03 last week after announcing it is in negotiations to acquire fellow Israeli stroke company Thrombotech Ltd....
BioCentury | Feb 28, 2012
Company News

D-Pharm seeking Thrombotech acquisition after Phase III halt

...D-Pharm Ltd. (Tel Aviv:DPRM) said it is in negotiations to acquire stroke company Thrombotech Ltd. (Ness Ziona...
...technology. The product has completed a Phase II trial in patients with complex partial epilepsy. Thrombotech's...
BioCentury | Jan 23, 2012
Financial News

Thrombotech completes venture financing

Thrombotech Ltd. , Ness Ziona, Israel Business: Cardiovascular Date completed: 1/18/12 Type: Venture financing Raised: $1.4 million Investors: Clal Biotechnology Industries; Ofer Hi-Tech Group; Hadasit WIR Staff Cardiovascular...
Items per page:
1 - 10 of 12
BioCentury | Jan 5, 2015
Clinical News

THR-18: Additional Phase IIa data

...D-Pharm, which previously reported interim data from the trial, gained THR-18 through its merger with Thrombotech Ltd....
BioCentury | Mar 10, 2014
Clinical News

THR-18: Interim Phase IIa data

...to a second cohort evaluating 0.54 mg/kg THR-18. D-Pharm gained THR-18 through its merger with Thrombotech Ltd....
BioCentury | Oct 21, 2013
Clinical News

THR-18: Phase IIa start

...in about 30 patients with acute ischemic stroke. D-Pharm gained THR-18 through its merger with Thrombotech Ltd....
BioCentury | May 28, 2012
Company News

D-Pharm, Thrombotech deal

...D-Pharm will merge with stroke company Thrombotech in a stock deal. Shareholders of Thrombotech will own...
...own stroke therapy DP-b99 due to lack of efficacy. The combined company's pipeline will include: Thrombotech's...
...patients with complex partial epilepsy (see BioCentury, March 5). D-Pharm Ltd. (Tel Aviv:DPRM), Rehovot, Israel Thrombotech Ltd....
BioCentury | May 28, 2012
Finance

Highlights of weekly biotech stock moves

...after announcing it will merge with stroke company Thrombotech Ltd. in a stock deal. Shareholders of Thrombotech...
BioCentury | May 25, 2012
Company News

D-Pharm, Thrombotech to merge

...will merge with stroke company Thrombotech Ltd. (Ness Ziona, Israel) in a stock deal. Shareholders of Thrombotech...
...own stroke therapy DP-b99 due to lack of efficacy. The combined company's pipeline will include: Thrombotech's...
BioCentury | Mar 5, 2012
Company News

D-Pharm, Thrombotech deal

...D-Pharm said it is in negotiations to acquire stroke company Thrombotech in a stock deal after...
...technology. The product has completed a Phase II trial in patients with complex partial epilepsy. Thrombotech's...
...in Phase II testing to treat acute ischemic stroke. D-Pharm Ltd. (Tel Aviv:DPRM), Rehovot, Israel Thrombotech Ltd....
BioCentury | Mar 5, 2012
Finance

Highlights of weekly biotech stock moves

...NIS1.03 last week after announcing it is in negotiations to acquire fellow Israeli stroke company Thrombotech Ltd....
BioCentury | Feb 28, 2012
Company News

D-Pharm seeking Thrombotech acquisition after Phase III halt

...D-Pharm Ltd. (Tel Aviv:DPRM) said it is in negotiations to acquire stroke company Thrombotech Ltd. (Ness Ziona...
...technology. The product has completed a Phase II trial in patients with complex partial epilepsy. Thrombotech's...
BioCentury | Jan 23, 2012
Financial News

Thrombotech completes venture financing

Thrombotech Ltd. , Ness Ziona, Israel Business: Cardiovascular Date completed: 1/18/12 Type: Venture financing Raised: $1.4 million Investors: Clal Biotechnology Industries; Ofer Hi-Tech Group; Hadasit WIR Staff Cardiovascular...
Items per page:
1 - 10 of 12